ALA Prophylactic Agent for Anticancer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents often cause severe side effects due to their potent nature, and existing methods to alleviate these side effects are either ineffective or come with significant healthcare burdens, including costly molecular target drugs with side effects of their own.
Innovation Solution
A prophylactic and therapeutic agent comprising 5-aminolevulinic acid (ALA) or its derivatives, potentially combined with metals like iron, magnesium, or zinc, which can be administered before, during, or after anticancer therapy to mitigate side effects without compromising the anticancer effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If potent anticancer agents are used to achieve stronger anticancer effect, then the anticancer effect is improved, but the side effects worsen
Solution Approach 1:
ALA acts as an intermediary substance that selectively protects normal cells from anticancer agent damage while leaving cancer cells vulnerable. The compound accumulates in normal cells and converts to PPIX, which then protects these cells when exposed to anticancer agents, thereby mediating between the drug's anticancer action and its harmful side effects on normal tissues
Solution Approach 2:
The invention exploits the local quality difference between normal and cancer cells in their ability to metabolize ALA. Normal cells efficiently convert ALA to heme and excrete it, while cancer cells accumulate PPIX and cannot properly metabolize ALA. This local metabolic difference allows selective protection of normal cells without compromising the anticancer effect
2Object-affected harmful factors
If agents that suppress side effects of anticancer agent are administered, then the side effects are reduced, but the anticancer effect is also suppressed
Solution Approach 1:
The invention converts the harmful effect of ALA accumulation in normal cells into a beneficial protective mechanism. The same metabolic pathway that normally processes ALA is exploited to create PPIX, which then serves as a protective agent against anticancer drug toxicity. The substance that would normally be considered a metabolic byproduct becomes the key protective element
3Object-affected harmful factors
If molecular target drugs are used to achieve selective anticancer action, then the side effects are reduced, but the cost increases significantly
Solution Approach 1:
ALA is a inexpensive, naturally occurring compound that can be administered orally or intravenously. Unlike expensive molecular target drugs, ALA works through a simple metabolic pathway that is already present in normal cells, making it a cost-effective solution. The compound is rapidly metabolized and excreted, eliminating the need for expensive long-term treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of ALA effectively reduces and prevents side effects of anticancer agents, allowing for increased administration doses and improved quality of life, while maintaining the anticancer effect, and can be used in combination with existing treatments for additive or synergistic benefits.
Implementation Method 1
PPD is possible because fluorescence is emitted when light is irradiated on the accumulated PPIX
Implementation Method 2
in the presence of oxygen, PDT is possible because reactive oxygen is produced when light is irradiated on the accumulated PPIX
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
Problem to be Solved A prophylactic and/or therapeutic agent for side effects of anticancer agent is provided. Solution The present invention provides a prophylactic and/or therapeutic agent for side effects of anticancer agent comprising ALAs.